Alligator Bioscience has announced a letter-of-intent (LOI) with Unicancer regarding mitazalimab, outlining a potential path toward a Phase III program and signalling external interest in advancing the asset. We view the update as positive and consider the share price reaction of around 20% to be reasonable given the improved visibility on a potential way forward.
LÄS MER
